JP2020536916A - 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 - Google Patents

抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 Download PDF

Info

Publication number
JP2020536916A
JP2020536916A JP2020520535A JP2020520535A JP2020536916A JP 2020536916 A JP2020536916 A JP 2020536916A JP 2020520535 A JP2020520535 A JP 2020520535A JP 2020520535 A JP2020520535 A JP 2020520535A JP 2020536916 A JP2020536916 A JP 2020536916A
Authority
JP
Japan
Prior art keywords
drug conjugate
antibody drug
administered
antibody
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020520535A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536916A5 (enExample
Inventor
マンレイ，トーマス
ジョセフソン，ニール
Original Assignee
シアトル ジェネティクス，インコーポレイティド
シアトル ジェネティクス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シアトル ジェネティクス，インコーポレイティド, シアトル ジェネティクス，インコーポレイティド filed Critical シアトル ジェネティクス，インコーポレイティド
Publication of JP2020536916A publication Critical patent/JP2020536916A/ja
Publication of JP2020536916A5 publication Critical patent/JP2020536916A5/ja
Priority to JP2023116434A priority Critical patent/JP7750902B2/ja
Priority to JP2025158913A priority patent/JP2026001086A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2020520535A 2017-10-11 2018-10-11 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 Withdrawn JP2020536916A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023116434A JP7750902B2 (ja) 2017-10-11 2023-07-18 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法
JP2025158913A JP2026001086A (ja) 2017-10-11 2025-09-25 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762570901P 2017-10-11 2017-10-11
US62/570,901 2017-10-11
US201762580267P 2017-11-01 2017-11-01
US62/580,267 2017-11-01
US201862639308P 2018-03-06 2018-03-06
US62/639,308 2018-03-06
US201862764805P 2018-08-16 2018-08-16
US62/764,805 2018-08-16
PCT/US2018/055354 WO2019075168A2 (en) 2017-10-11 2018-10-11 METHODS OF REDUCING SIDE EFFECTS OF DRUG-CONJUGATED DRUG THERAPY ANTI-CD30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023116434A Division JP7750902B2 (ja) 2017-10-11 2023-07-18 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法

Publications (2)

Publication Number Publication Date
JP2020536916A true JP2020536916A (ja) 2020-12-17
JP2020536916A5 JP2020536916A5 (enExample) 2021-11-25

Family

ID=64477266

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020520535A Withdrawn JP2020536916A (ja) 2017-10-11 2018-10-11 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法
JP2023116434A Active JP7750902B2 (ja) 2017-10-11 2023-07-18 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法
JP2025158913A Pending JP2026001086A (ja) 2017-10-11 2025-09-25 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023116434A Active JP7750902B2 (ja) 2017-10-11 2023-07-18 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法
JP2025158913A Pending JP2026001086A (ja) 2017-10-11 2025-09-25 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法

Country Status (14)

Country Link
US (1) US11795229B2 (enExample)
EP (1) EP3694559A2 (enExample)
JP (3) JP2020536916A (enExample)
KR (2) KR20200066676A (enExample)
CN (1) CN111526893A (enExample)
AU (1) AU2018347406B2 (enExample)
BR (1) BR112020006892A2 (enExample)
CA (1) CA3078737A1 (enExample)
IL (2) IL316538A (enExample)
MA (1) MA50767A (enExample)
MX (1) MX2020003664A (enExample)
SG (1) SG11202003352SA (enExample)
TW (1) TW201922281A (enExample)
WO (1) WO2019075168A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023536873A (ja) * 2020-08-03 2023-08-30 ジェネンテック， インコーポレイテッド 侵襲性非ホジキンリンパ腫における忍容性の予測

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102770340B1 (ko) 2020-06-02 2025-02-21 삼성디스플레이 주식회사 표시 패널 및 이를 구비하는 표시 장치

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
ES2129029T5 (es) 1990-10-05 2005-10-16 Celldex Therapeutics, Inc. Inmunoestimulacion dirigida con reactivos biespecificos.
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
CA2108451A1 (en) 1991-04-26 1992-10-27 Beverley J. Randle Novel antibodies, and methods for their use
ES2193143T3 (es) 1992-03-05 2003-11-01 Univ Texas Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
WO2005084390A2 (en) 2004-03-02 2005-09-15 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
EP1828241A1 (en) * 2004-12-23 2007-09-05 Laboratoires Serono S.A. G-csf polypeptides and uses thereof
CA2699090C (en) * 2007-10-12 2016-02-02 Seattle Genetics, Inc. Combination therapy with antibody-drug conjugates
CA3051090C (en) 2009-01-09 2022-04-12 Seattle Genetics, Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CASSADAY, R. D. ET AL: "Safety and Activity of Brentuximab Vedotin(BV) Plus Ifosfamide, Carboplatin, and Etoposide(ICE) for", BLOOD, vol. Vol.128(22): 1834, JPN6022039728, 2016, ISSN: 0005014546 *
FDA: "HIGHLIGHTS OF PRESCRIBING INFORMATION", FDA, ADCETRIS [ONLINE], JPN5021002078, November 2014 (2014-11-01), pages 1 - 19, ISSN: 0005014544 *
FEDERICO, M. ET AL: "Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin", HAEMATOLOGICA, vol. Vol.101:e139, JPN6022039732, 2016, ISSN: 0005014543 *
GARCIA-SANZ, R. ET AL: "Brentuximab Vedotin Plus ESHAP(BRESHAP) Is a Highly Effective Combination for Inducing Remission in", BLOOD, vol. Vol.128(22):1109, JPN6022039730, 2016, ISSN: 0005014545 *
RENWICK, W. ET AL: "Use of Filgrastim and Pegfilgrastim to Support Delivery of Chemotherapy", BIODRUGS, vol. Vol.23(3), JPN6022039735, 2009, pages 175 - 186, ISSN: 0005014548 *
VEHRESCHILD, J. J. ET AL: "Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients und", ANNALS OF ONCOLOGY, vol. 25, JPN6022039733, 2014, pages 1709 - 1718, XP009512558, ISSN: 0005014547, DOI: 10.1093/annonc/mdu035 *
YOUNES, A. ET AL: "Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma:", LANCET ONCOL, vol. 14, JPN6022039734, 2013, pages 1348 - 1356, XP093105263, ISSN: 0005014549, DOI: 10.1016/S1470-2045(13)70501-1 *
高野 利実: "支持療法", ＪＳＣＯ, vol. 49, no. 2, JPN6023010537, 2014, pages 401 - 410, ISSN: 0005014550 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023536873A (ja) * 2020-08-03 2023-08-30 ジェネンテック， インコーポレイテッド 侵襲性非ホジキンリンパ腫における忍容性の予測

Also Published As

Publication number Publication date
CA3078737A1 (en) 2019-04-18
KR20200066676A (ko) 2020-06-10
MX2020003664A (es) 2020-10-12
JP7750902B2 (ja) 2025-10-07
MA50767A (fr) 2020-08-19
AU2018347406B2 (en) 2025-09-04
US11795229B2 (en) 2023-10-24
AU2018347406A1 (en) 2020-04-23
US20210221901A1 (en) 2021-07-22
KR20250117487A (ko) 2025-08-04
TW201922281A (zh) 2019-06-16
WO2019075168A2 (en) 2019-04-18
JP2023162163A (ja) 2023-11-08
WO2019075168A3 (en) 2019-05-23
BR112020006892A2 (pt) 2020-10-06
IL273874A (en) 2020-05-31
EP3694559A2 (en) 2020-08-19
IL316538A (en) 2024-12-01
CN111526893A (zh) 2020-08-11
SG11202003352SA (en) 2020-05-28
JP2026001086A (ja) 2026-01-06

Similar Documents

Publication Publication Date Title
JP7241207B2 (ja) Ｔｉｇｉｔおよびｐｄ－１／ｔｉｇｉｔ結合分子
JP2026001086A (ja) 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法
US20240245753A1 (en) Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
JP2025166117A (ja) 腫瘍性疾患のための治療
US20200102399A1 (en) Methods of Treating Peripheral T Cell Lymphoma Using Anti-CD30 Antibody Drug Conjugate Therapy
TW201801746A (zh) Cd33抗體藥物結合物與化學治療劑之組合
JP7422070B2 (ja) 癌の治療のための配合剤
JP7659546B2 (ja) 造血器がんの治療のための抗ｃｄ３０ ａｄｃ、抗ｐｄ－１、および化学療法剤の併用
HK40077034A (en) Combination anti-cd30 adc, anti-pd-1 and chemotherapeutic for treatment of hematopoietic cancers
HK40040881A (en) Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
CN112439060A (zh) Pd-l1免疫疗法的新用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230718

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20231122